{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:00:55Z","timestamp":1778788855669,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.anndiagpath.2022.151931","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:50:04Z","timestamp":1646221804000},"page":"151931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immune characterization of thyroid neoplasm's and its variants using immunohistochemical markers: CK-19, Galectin-3 and Hector Battifora mesothelial-1"],"prefix":"10.1016","volume":"58","author":[{"given":"Shamaila","family":"Nehal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranati","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayasree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urmila","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151931_bb0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/ijerph13040442","article-title":"The prevalence of thyroid nodules and an analysis of related lifestyle factors in Beijing communities","volume":"13","author":"Jiang","year":"2016","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"10.1016\/j.anndiagpath.2022.151931_bb0010","first-page":"277","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151931_bb0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ando.2009.11.006","article-title":"Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival","volume":"71","author":"Colonna","year":"2010","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.anndiagpath.2022.151931_bb0020","author":"American Cancer Society"},{"issue":"15_suppl","key":"10.1016\/j.anndiagpath.2022.151931_bb0025","doi-asserted-by":"crossref","first-page":"e18095","DOI":"10.1200\/JCO.2018.36.15_suppl.e18095","article-title":"Trends in thyroid cancer incidence in India","volume":"36","author":"Veedu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.anndiagpath.2022.151931_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1746-1596-5-9","article-title":"Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroidnodules","volume":"26","author":"Saleh","year":"2010","journal-title":"Diagn Pathol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151931_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0971-5851.99746","article-title":"Cytokeratin 19 immunoreactivity inthe diagnosis of papillary thyroid carcinoma","volume":"33","author":"Bose","year":"2012","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151931_bb0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/modpathol.3800235","article-title":"Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19immunohistochemistry is useful for the differential diagnosis of thyroid tumors","volume":"18","author":"Prasad","year":"2005","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151931_bb0045","first-page":"257","article-title":"Expression ofTTF-1 in thyroid tumors originating from follicular epithelium and its correlation with expression of RET, galectin-3 and mucin-1 genes","volume":"82","author":"Chen","year":"2002","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.anndiagpath.2022.151931_bb0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13000-015-0428-4","article-title":"Defining the value of CD56, CK19, galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature","volume":"10","author":"Dun\u0111erovi\u0107","year":"2015","journal-title":"Diagn Pathol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151931_bb0055","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4103\/JLP.JLP_106_17","article-title":"Value of cytokeratin-19, Hector Battifora mesothelial-1 and galectin-3immunostaining in the diagnosis of thyroid neoplasms","volume":"10","author":"Sanuvada","year":"2018","journal-title":"J Lab Physicians"},{"issue":"10","key":"10.1016\/j.anndiagpath.2022.151931_bb0060","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0046-8177(99)90033-3","article-title":"Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility","volume":"30","author":"Baloch","year":"1999","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2022.151931_bb0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1365-2559.2002.01442.x","article-title":"Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules","volume":"41","author":"Beesley","year":"2002","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2022.151931_bb0070","first-page":"86","article-title":"Usefulness of galectin-3, cytokeratin 19, p53 and Ki-67 for the differential diagnosis of thyroid tumors","volume":"40","author":"Moon","year":"2006","journal-title":"Korean J Pathol"},{"issue":"21","key":"10.1016\/j.anndiagpath.2022.151931_bb0075","first-page":"49","article-title":"CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions","volume":"14","author":"Erdogan-Durmus","year":"2016","journal-title":"J Res Med Sci"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151931_bb0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2559.2005.02221.x","article-title":"Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy","volume":"47","author":"de Matos","year":"2005","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.anndiagpath.2022.151931_bb0085","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.prp.2014.06.010","article-title":"Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules","volume":"210","author":"Abd-El Raouf","year":"2014","journal-title":"Pathol Res Pract"},{"issue":"11","key":"10.1016\/j.anndiagpath.2022.151931_bb0090","article-title":"Galectin-3 immunohistochemical expression in thyroid neoplasms","volume":"9","author":"Sumana","year":"2015","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151931_bb0095","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.3892\/ol.2017.6719","article-title":"Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer","volume":"14","author":"Arcolia","year":"2017","journal-title":"Oncol Lett"},{"issue":"8","key":"10.1016\/j.anndiagpath.2022.151931_bb0100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/dc.20841","article-title":"HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma","volume":"36","author":"Nga","year":"2008","journal-title":"Diagn Cytopathol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2022.151931_bb0105","first-page":"8130","article-title":"Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: a meta-analysis","volume":"10","author":"Xin","year":"2017","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:34:35Z","timestamp":1761078875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913422000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":21,"alternative-id":["S1092913422000338"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151931","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune characterization of thyroid neoplasm's and its variants using immunohistochemical markers: CK-19, Galectin-3 and Hector Battifora mesothelial-1","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151931"}}